Genomics of <i>Helicobacter pylori</i>

Thorell, Kaisa; Lehours, Philippe; Vale, Filipa F.

doi:10.1111/hel.12409

Cited by 23 publications

(17 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Two well‐defined clinical entities provide a vivid illustration of disrupted microbiome‐host interactions: Clostridioides difficile‐ associated disease (CDAD) and Helicobacter pylori infection. The former serves as a dramatic reminder of the consequences of iatrogenic disruptions of a microbiome that, when intact, serves to protect us against pathogens (Britton & Young, ; Schäffler & Breitrück, ), and the latter exemplifies how host genome, bacterial properties and the immune response conspire to produce various disease phenotypes (Noto & Peek, ; Thorell, Lehours, & Vale, ; Waskito, Salama, & Yamaoka, ).…”

Section: What Do We Know?mentioning

confidence: 99%

Nutraceuticals as modulators of gut microbiota: Role in therapy

Quigley

2020

British J Pharmacology

View full text Add to dashboard Cite

As our knowledge of the various roles of the gut microbiota in the maintenance of homeostasis grows and as we learn how a disrupted microbiota may contribute to disease, therapeutic strategies that target our microbial fellow‐travellers become ever more attractive. Most appealing are those interventions that seek to modify or supplement our diet through the addition of nutraceuticals. We now know that our diet, whether in the short or long term, is a major modifier of microbiota composition and function. Of the various nutraceuticals, two categories, prebiotics and probiotics, have received the greatest attention in basic research and product development. While our understanding of the impacts of prebiotics and probiotics on the indigenous microbiota and host biology have been described in great detail in vitro and in animal models, the clinical literature leaves much to be desired. While many claims have been made, few are supported by high quality clinical trials. Linked Articles This article is part of a themed section on The Pharmacology of Nutraceuticals. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.6/issuetoc

show abstract

Section: What Do We Know?mentioning

confidence: 99%

Nutraceuticals as modulators of gut microbiota: Role in therapy

Quigley

2020

British J Pharmacology

View full text Add to dashboard Cite

show abstract

“…In fact there is evidence of high adaptability to the new environment, with new subpopulations of H. pylori constantly emerging in different regions of the world. Recent studies highlighted that in the span of 500 years of migration to the Latin America, already there have been sequenced distinct genomes specific to these populations [11]. This diversity is also present when analyzing severity of the infection across the world, and manifests itself is in virulence factors.…”

Section: State Of the Knowledgementioning

confidence: 99%

Expanding the knowledge of Helicobacter pylori – new directions, new challenges

Wronecki¹,

Tywanek²,

Trojanowska³

et al. 2020

J Educ Health Sport

View full text Add to dashboard Cite

show abstract

“…These studies have shown that H . pylori display extensive intraspecies diversity 18 and that this diversity appears to be influenced by the presence of mobile genomic elements, including prophages 9 …”

Section: Introductionmentioning

confidence: 99%

An American lineage of Helicobacter pylori prophages found in Colombia

2021

Self Cite

View full text Add to dashboard Cite

Background Helicobacter pylori is a human gastric carcinogen that is highly prevalent in Latin American. The prophages of H. pylori show a structured population and contribute to the diversity of this bacterium. However, H. pylori prophages present in American strains have not been described to date. In this study, we identified, characterized, and present the phylogenetic analysis of the prophages present in Colombian H. pylori strains. Methods To characterize Colombian H. pylori strains and their prophages, a Multilocus Sequences Typing (MLST) and a Prophage Sequences Typing (PST), using the integrase and holin genes, were performed. Furthermore, five Colombian H. pylori had their full genome sequenced, and six Colombian H.pylori retrieved from databases, allowing to determine the prophage complete genome and insertion site. Results The integrase gene frequency was 12.6% (27/213), while both integrase and holin genes were present in 4.2% (9/213) of the samples analyzed. The PST analysis showed that Colombian prophages belong to different populations, including hpSWEurope, hpNEurope, hpAfrica1, and a new population, named hpColombia. The MLST analysis classified most of the Colombia strains in the hpEurope population. Conclusions The new H. pylori prophage population revealed that Colombian prophages follow a unique evolutionary trajectory, contributing to bacterial diversity. The global H. pylori prophage phylogeny highlighted five phylogenetic groups, one more than previously reported. After the arrival of Europeans, the Colombian H. pylori bacteria and their prophages formed an independent evolutionary line to adapt to the new environment and new human hosts.

show abstract

Genomics of Helicobacter pylori

Cited by 23 publications

References 35 publications

Nutraceuticals as modulators of gut microbiota: Role in therapy

Nutraceuticals as modulators of gut microbiota: Role in therapy

Expanding the knowledge of Helicobacter pylori – new directions, new challenges

An American lineage of Helicobacter pylori prophages found in Colombia

Contact Info

Product

Resources

About